Health Insurance (Permitted Benefits – Pathology Services) Determination 2018

The central concept is a “permitted benefit” under section 23DZZIG of the Health Insurance Act. The determination defines which benefits are permitted, and the Act itself presumably prohibits the giving or receiving of non-permitted benefits (though the determination does not recite that prohibition). Key defined terms are incorporated by reference from the Act: “accredited pathology laboratory”, “approved pathology practitioner”, “hospital” and “pathology service” are defined in subsection 3(1) of the Act; “provider” and “requester” are defined in subsection 23DZZID(1). “Beneficiary” is not defined in the instrument but appears in section 6 and seems to refer to the requester or a person connected to the requester. The benefit must be asked for, accepted, offered or provided by or to a “beneficiary who is, or is connected to, a requester” (s 6(1)(a) and (b)). The term “connected to” is not defined in the instrument, creating some interpretive uncertainty about how far the prohibition extends (e.g. whether it covers family members, practice staff, or corporate entities). The two operative prohibitions in section 6(2) are critical. The first, in paragraph (a), targets benefits that are “related to the number, kind or value of requests for pathology services made by a requester to a particular provider”. This is a direct anti-kickback rule: a free refrigerator or educational session cannot be tied to how many referrals a doctor sends to a particular lab. The second, in paragraph (b), caps the quantity of benefits of any kind to what “would usually be needed by the beneficiary’s practice”. This prevents stockpiling or the provision of duplicative items that could be converted to personal use or sold. Schedule 1 enumerates nine categories of permitted benefit. Category 1 covers items that help the requester make requests or view reports, usable only for pathology purposes (software is given as an example). Categories 2 and 3 permit provision of certain staff and equipment at the beneficiary’s premises, but only for specific procedures (fine needle aspiration, bone marrow aspiration or trephine, frozen section examination) or, in the case of a hospital, for collecting specimens from patients receiving hospital treatment. Category 4 covers educational material about pathology (including patient handouts). Category 5 covers education sessions, subject to six conditions: primary educational objective, appropriate venue, hospitality secondary, reasonable cost, no travel or accommodation paid by provider, and no sporting event or other entertainment. Category 6 covers gifts or hospitality on significant occasions, non-cash, infrequent, not an inducement, and reasonable cost. Category 7 covers pathology request forms, telephone result pads, stock request pads, promotional publications and items, provided they have no resale value and are identified as coming from the provider. Category 8 covers equipment necessary for collection, identification or temporary storage of specimens, such as refrigerators, insulated containers, specimen pick-up receptacles, all labelled as the provider’s property and used exclusively for pathology. Category 9 is a detailed table of 30 items of consumable collection goods (needle holders, vacutainers, syringes, slides, transport media, etc.), supplied by an accredited pathology laboratory to referrers, and when other uses are possible, the goods “will only be used for collection purposes” - a condition that rests on an expectation of use rather than a legal prohibition. Together, the schedule creates a detailed code of what is permissible, balancing clinical necessity and professional courtesy against the risk of inducement.

The determination directly affects three categories of actors: providers of pathology services (typically accredited pathology laboratories and approved pathology practitioners), requesters of pathology services (medical practitioners who order tests), and beneficiaries connected to requesters (which could include practice staff or family members, though the scope is ambiguous). Hospitals are specifically addressed in category 2(b) and 3(b), where the provision of staff and equipment for specimen collection is permitted if the patient is receiving hospital treatment. The determination does not directly impose obligations on patients, but patients may be recipients of educational material (category 4) or indirectly benefit from improved specimen collection equipment. Providers and requesters are the primary regulated entities. A provider who offers a benefit that is not permitted under this determination risks that the benefit will be treated as an unlawful inducement under the Health Insurance Act, potentially jeopardising Medicare benefits for the related services. Requesters who accept non-permitted benefits may also be in breach. The determination is relevant to any business arrangement between pathology laboratories and referring doctors. For example, a lab that provides free courier services or subsidised practice management software must check that these fall within an enumerated category or otherwise satisfy section 6. The conditions in Schedule 1 are strict: for instance, education sessions cannot include payment of travel or accommodation (category 5(e)), and gifts can only be given infrequently and on significant occasions (category 6(b)). This means that routine gifts (e.g. branded pens or calendars) likely fall outside category 6, but might be caught by category 7 as promotional items if they have no resale value and are identified as from the provider. The determination also affects pathology practitioners who are stationed at a requester’s premises: they are permitted only for the sole purpose of providing preliminary analysis or advice for three specific procedures (fine needle aspiration, bone marrow aspiration/trephine, frozen section). Any broader deployment of staff would not be a permitted benefit. Similarly, equipment at the requester’s premises is limited to those same procedures or, in hospitals, to specimen collection from hospital treatment patients. This creates a clear boundary: a lab cannot, for example, place a full-time phlebotomist in a general practice for routine blood collection unless the practice is a hospital and the collection is from a hospital treatment patient. The narrowness of categories 2 and 3 reflects a policy choice to permit only direct clinical support for high-acuity or urgent procedures, rather than ongoing logistical support. The determination also affects the supply chain: category 9 permits an accredited pathology laboratory to supply a specific list of consumables to referrers, but only if the goods will be used solely for collection purposes when other uses are possible. This puts the onus on the laboratory to ensure that items like syringes or alcohol wipes are not diverted to other clinical uses. In practice, laboratories that supply these items must have systems to confirm that the referrer uses them only for pathology specimen collection.

The determination does not create duties in the usual sense of imposing positive obligations. Instead, it establishes a set of conditions under which certain benefits are permissible. The principal prohibition is implied: if a benefit is not a permitted benefit under this determination, then the giving or receiving of that benefit in connection with pathology services is likely unlawful under the Health Insurance Act. The determination therefore creates a right for providers and requesters to give and receive the listed benefits without fear of breaching the Act, provided they comply with the conditions. But there is no right to demand any particular benefit; the determination is permissive, not mandatory. The duties that arise are largely negative: do not offer or accept benefits tied to the number or value of referrals (s 6(2)(a)), and do not provide benefits in excess of what would usually be needed by the practice (s 6(2)(b)). These two prohibitions apply even to benefits that appear in Schedule 1. For example, a histopathology practice could supply a refrigerator under category 8, but if the fridge is provided on condition that the doctor sends all biopsies to that practice, it falls foul of s 6(2)(a) because it is related to the number or value of requests. Similarly, supplying five refrigerators to a solo practice would likely breach s 6(2)(b) because one would satisfy usual needs. The conditions within Schedule 1 create additional duties. For category 5 (education sessions), the provider must ensure the venue is appropriate, hospitality is secondary, costs are reasonable, and no travel or accommodation is paid. For category 7, promotional items must have no resale value and be clearly identified as coming from the provider. For category 8, equipment must be labelled as the provider’s property and used exclusively for pathology purposes. For category 9, the goods must be supplied by an accredited pathology laboratory and, when other uses are possible, the goods “will only be used for collection purposes”. This last condition is notable: it is not phrased as a legal prohibition on the recipient using the goods for other purposes, but rather as a condition of the benefit being permitted. If the recipient later uses a syringe for an injection rather than specimen collection, the original supply may become a non-permitted benefit. This places practical risk on the laboratory to ensure compliance by its referrers. The determination also raises interpretive duties: providers must assess whether a particular benefit is “related to” the number, kind or value of requests (s 6(2)(a)). This could capture indirect links, such as a loyalty program that offers benefits based on cumulative referrals. The phrase “taken with other benefits of the same kind” (s 6(2)(b)) requires aggregating benefits across time and possibly across multiple providers - a challenging compliance task for a laboratory that supplies multiple referrers. Finally, the determination does not confer any private right of action on patients or competitors. Enforcement is a matter for the Department of Health or other authorities under the Health Insurance Act.

The determination itself does not prescribe penalties. It is a legislative instrument made under section 23DZZIG of the Health Insurance Act, and its operative effect is to define what is a “permitted benefit”. The enforcement framework resides in the Health Insurance Act. Although the source text does not reproduce the penalty provisions, a careful reader knows that section 23DZZIG is part of a division dealing with prohibited practices relating to pathology services. Under the Act, giving or receiving a benefit that is not a permitted benefit likely constitutes an offence. The penalties could include civil penalties, criminal fines, or the loss of Medicare benefits for the services involved. The determination functions as a defence or safe harbour: if a benefit meets the conditions, it is deemed permitted and therefore lawful. If it does not, the onus shifts to the parties to justify the benefit under the Act’s general provisions, or face enforcement action. The absence of specific penalty amounts in the determination is consistent with its role as a definitional instrument. For compliance purposes, the risk is that an arrangement falls outside the permitted list and is subsequently challenged. The Department of Health may issue advisory opinions or conduct audits. The determination also interacts with the professional standards of medical practitioners and pathology providers. A breach could lead to referral to the Australian Health Practitioner Regulation Agency or the Professional Services Review scheme, which examines inappropriate practice under the Medicare program. The determination thus has a dual regulatory effect: it is part of the legal framework for Medicare compliance and also informs professional ethical standards. The example of a pathologist providing free phlebotomy services to a general practice not involving the three specified procedures would not be a permitted benefit, exposing both parties to potential enforcement. The fact that the determination only permits staff stationed for “preliminary analysis or advice” for the three procedures, and not for specimen collection or handling, indicates a deliberate restriction. In practice, enforcement likely focuses on arrangements that appear to be inducements, such as free rent, free staff, or free equipment that goes beyond the schedule. The determination provides clarity for the industry, but the ultimate penalty for non-compliance can be severe: exclusion from Medicare, repayment of benefits, or criminal prosecution. Regulatory guidance from the Department (not part of this instrument) may elaborate on enforcement priorities, but the determination itself is silent.

The determination must be read as part of the Health Insurance Act framework, particularly Part IID, Division 2 (as amended). Section 23DZZIG is the specific head of power. The Act’s other provisions on prohibited benefits, including the definition of “requester” and “provider”, directly inform the determination’s scope. The determination also interacts with the Private Health Insurance Act 2007 through the definition of “hospital treatment” in section 121-5 of that Act, which is incorporated by reference in the determination’s definitions. This matters because categories 2(b) and 3(b) allow staff and equipment at a hospital for collecting specimens from a person “in attendance at the hospital for the purpose of receiving hospital treatment”. That phrase is not further defined in the determination, so one must look to the Private Health Insurance Act to determine whether day surgery or outpatient chemotherapy qualifies. If a person is in hospital for a consultation only, not treatment, the benefit may not be permitted. The determination also interacts with state and territory health legislation, though it does not purport to override state law. For instance, the supply of medical devices (like syringes and needles) is regulated by state therapeutic goods laws; the determination does not create an exemption from those laws. It also interacts with the Competition and Consumer Act 2010, because some benefits could involve exclusive dealing or anti-competitive conduct. A laboratory that supplies free refrigerators only to doctors who refer exclusively to it may breach both the determination (if the benefit is tied to number of requests) and competition law. The determination does not address that interplay. It also coexists with professional codes of conduct from the Australian Medical Association and the Royal College of Pathologists of Australasia, which may impose stricter standards. For example, the AMA code discourages gifts of any value from pharmaceutical or pathology companies, whereas the determination permits reasonable gifts on significant occasions. The determination sets the legal minimum; professional ethics may demand more. There is also an interaction with the Medicare Benefits Schedule itself, because the benefit is only relevant if the pathology service is eligible for Medicare. The determination does not alter the listing of pathology services; it only governs the ancillary benefits that may be offered alongside those services. Finally, the determination repealed the 2008 determination, so any transitional arrangements for benefits that were permitted under the old determination but are not permitted under the new one would rely on general transitional provisions in the Act, if any. The instrument does not include a savings clause.

The instrument was made on 21 March 2018 by David Weiss, delegate of the Minister for Health, and commenced on the day after registration. It repeals and replaces the Health Insurance (Permitted benefits - pathology services) Determination 2008. The text of this determination as provided does not list any amendments to itself. It is a single instrument with no variation history shown. However, because it is a legislative instrument subject to the Legislation Act 2003, any future amendments would be published on the Federal Register of Legislation. As of the date of this deep dive, no amending instruments have been identified in the supplied text. The repeal of the 2008 determination means that the previous list of permitted benefits no longer applies. Practitioners relying on the old determination must ensure their arrangements fit within the 2018 rules. The most significant change from the 2008 determination is not visible from the text alone, but comparing the schedules would reveal any differences. The 2018 determination continues the structure of a list of permitted benefits with conditions. It also updates the definitions to cross-reference the Private Health Insurance Act 2007 for “hospital treatment”, which reflects amendments to the private health insurance regime. There is no amending history within the instrument itself, but the instrument has been in force since 2018 and may have been affected by later amendments to the Health Insurance Act (such as changes to section 23DZZIG). The user’s source does not include those amendments, so we cannot comment on them.

The source text does not reference any court cases or tribunal decisions. The determination itself is an administrative instrument and is unlikely to be directly litigated; challenges would more likely involve the underlying provisions of the Health Insurance Act. There have been Federal Court cases on what constitutes an “inducement” or “benefit” under the Act, but none are cited in this instrument. The determination provides a safe harbour, so litigation might test the boundaries of that safe harbour - for example, whether a particular arrangement falls within Schedule 1 or whether the “exceeds what would usually be needed” test in section 6(2)(b) is breached. Without case law, the terms “usually needed” and “related to the number, kind or value of requests” remain undefined. Any dispute would likely be heard by the Administrative Appeals Tribunal on review of a decision by the Department to deny Medicare benefits or impose a penalty. There is no record of such a review in the supplied material. The determination has been in force for over six years without apparent high-profile litigation, suggesting that the industry generally complies or that disputes are resolved without public judgment. However, the lack of litigation does not mean the instrument is problem-free; it may indicate that the Department uses other enforcement tools (such as compliance letters) or that the arrangements fall within the safe harbour and are not contested. New arrangements, such as the provision of telepathology software or digital report viewers, may be tested. The determination’s category 1 (items that help view reports) may cover such software, but disputes could arise if the software has non-pathology uses. The litigation history is essentially a blank slate, which itself is notable: the determination’s specificity likely provides sufficient guidance to avoid disputes, or alternatively, the consequences of losing a case are so severe that parties settle early.

Several provisions contain traps for the unwary. First, the condition in category 9 that goods “will only be used for collection purposes” when other uses are possible is a promise about future use, not a legal prohibition. If the referrer uses a syringe for another purpose, the supply retroactively becomes non-permitted. The laboratory bears the risk of ensuring compliance. Second, categories 2 and 3 only permit staff and equipment at the beneficiary’s premises for the “sole purpose” of providing “preliminary analysis or advice” for three specific procedures. Routine phlebotomy or specimen collection at a doctor’s surgery (outside a hospital) is not covered. Many practices arrange for a pathology collector to attend daily to take bloods; that arrangement would not be a permitted benefit under this determination, even if the collector is an employee of the pathology laboratory. The only exception is for hospitals collecting specimens from hospital treatment patients (category 2(b) and 3(b)). This is a major limitation that may be overlooked. Third, the gift/hospitality category (category 6) is extremely narrow: non-cash, not convertible to cash, infrequent, only in relation to a “significant occasion”, and not an inducement. A Christmas party (the example) may be permitted, but a regular monthly dinner would not be. The cost must be “reasonable in the circumstances” - a vague standard. Fourth, the education session category (category 5) prohibits paying travel or accommodation costs for the beneficiary. Many CPD events routinely cover doctor’s travel; if a pathology provider sponsors such an event, it must ensure that no travel or accommodation for the referring doctor is paid by the provider. Fifth, the requirement in s 6(2)(b) that benefits not exceed what would “usually be needed by the beneficiary’s practice” is a subjective standard applied per benefit type. What is “usually needed” for a practice with three doctors might be different for a solo practitioner. A pathology provider that supplies the same number of specimen collection kits to all referrers could be in breach if some practices receive more than they need. Sixth, the term “connected to” in s 6(1) is undefined. It could extend to practice managers, receptionists, or even the doctor’s spouse. A benefit given to a practice manager could be imputed to the requester. Seventh, the benefit must be “in relation to” a kind of pathology service. If a provider offers a benefit that is not related to any specific pathology service but is a general practice benefit, it may not be permitted at all. Eighth, the determination does not cover benefits that are monetary or convertible to cash; such benefits are not in Schedule 1 and are likely never permitted. Ninth, category 7 requires promotional items to have “no resale value”. Items like pens or notepads have nominal resale value, but if they are branded and not sold on the open market, they may still be considered as having no realistic resale value. However, items like vouchers or gift cards have clear resale value and are prohibited. Tenth, the determination does not explicitly address benefits provided indirectly through third parties (e.g. a marketing company engaged by the laboratory). The chain of “person connected to a provider” may capture such indirect benefits.

Compliance begins with a clear understanding that any benefit given to a requester (or a person connected to a requester) must either be listed in Schedule 1 and meet its conditions, or otherwise satisfy the general test in s 6(1) while avoiding s 6(2). In practice, it is safest to limit benefits to those explicitly listed. For each benefit, document why it falls within a schedule category and verify that none of the prohibitions in s 6(2) apply. For example, if supplying a refrigerator (category 8), ensure it is labelled as the provider’s property, used exclusively for pathology purposes, and not provided in exchange for referrals. Implement periodic audits to confirm that the quantity of benefits supplied does not exceed “usually needed” levels for the practice. Especially for consumables in category 9, maintain records of what was supplied and to whom, and obtain written acknowledgment from the referrer that the goods will be used only for collection purposes. For education sessions (category 5), ensure the program has a clear educational objective, that hospitality is modest and incidental, and that no travel or accommodation costs are borne by the provider. If a laboratory offers a session with dinner, the dinner should be of reasonable cost and not the main focus. The venue should be chosen for its suitability for education, not for entertainment. Avoid any link between the session and the volume of referrals. For gifts (category 6), restrict them to non-cash items of modest value given only for significant life events (e.g. birth of a child, death in family, retirement). Do not give gifts that are convertible to cash. Keep a register of gifts given and ensure they are infrequent. For promotional items (category 7), confirm they have no resale value and display the provider’s identification. Software (category 1) must be usable only for pathology-related purposes; if the software has other uses (e.g. an electronic prescribing module), it may not be permitted. For staff placement (category 2), limit the staff member’s role to preliminary analysis or advice for fine needle aspiration, bone marrow aspiration/trephine, or frozen section. Do not place staff at a practice for routine blood collection unless the practice is a hospital and the patient is receiving hospital treatment. For hospitals, ensure that specimen collection staff are only used for patients who are receiving hospital treatment (not day-only consultations). Review any existing arrangements that were put in place under the 2008 determination; they may no longer be permitted. Finally, document compliance decisions and retain records for at least seven years. Seek legal advice if a benefit does not clearly fit within the schedule. The risk of non-compliance is not just civil penalty but also loss of Medicare benefits for pathology services, which could be financially devastating for a laboratory. A compliance program should include training for sales and marketing staff, contractual clauses with referrers requiring them to use supplied goods only for permitted purposes, and periodic internal audits. The determination does not require any formal reporting, but documentation is essential in the event of a Departmental review.